1. Breast cancer in BRCA mutation carriers: medical treatment.

    Minerva ginecologica 68(5):557 (2016) PMID 26799758

    About 10% of breast cancers are associated with the inheritance of autosomal dominant breast cancer susceptibility alleles BRCA1 and BRCA2. Until recently, the medical management of BRCA mutation-associated breast cancer has not differed from that of the sporadic breast cancer counterpart. Howev...
  2. Omission of axillary dissection after a positive sentinel lymph-node: Implications in the multidisciplinary treatment of operable breast cancer.

    Cancer Treatment Reviews 48:1 (2016) PMID 27262016

    Omission of axillary dissection in women with breast cancer and one or two positive sentinel-node biopsy is a major advancement in the management of this disease. Supported by a sound rationale and confirmed by prospective, randomized trials, omission of axillary dissection is now recommended in...
  3. Investigational ErbB-2 tyrosine kinase inhibitors for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 25(4):393 (2016) PMID 26863927

    ErbB2 overexpression and/or gene amplification is present in 20% of all breast cancers and characterizes an aggressive form of this disease. Despite the availability of several active drugs that have yielded substantial survival improvements, most patients with ErbB2-positive metastatic disease ...
  4. Linifanib: current status and future potential in cancer therapy.

    Expert Review of Anticancer Therapy 15(6):677 (2015) PMID 25936222

    Angiogenesis is one of the major mechanisms controlling tumor proliferation and metastatic spreading. Targeting of pro-angiogenic factors and their downstream effectors represents an appealing therapeutic option in the treatment of different cancer types. Linifanib (ABT-869) is a novel tyrosine-...
  5. Adjuvant Ovarian Suppression in Premenopausal Breast Cancer

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901437

    To the Editor: The results of the Suppression of Ovarian Function Trial (SOFT) by Francis et al. (Jan. 29 issue)1 are presented as practice changing. However, we are concerned about the emphasis given to the receipt of adjuvant chemotherapy — which was considered as a proxy for a disea...
  6. Adjuvant ovarian suppression in premenopausal breast cancer.

    New England Journal of Medicine 372(17):1672 (2015) PMID 25901438

  7. Higher Risk of Infections with PI3K-AKT-mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials.

    Clinical Cancer Research 21(8):1869 (2015) PMID 25649020 PMCID PMC4401558

    Novel antitumor therapies against the PI3K-AKT-mTOR pathway are increasingly used to treat cancer, either as single agents or in combination with chemotherapy or other targeted therapies. Although these agents are not known to be myelosuppressive, an increased risk of infection has been reported...
  8. Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer.

    Expert Opinion on Investigational Drugs 24(3):421 (2015) PMID 25645727

    Deregulation of the phosphatidylinositol-3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) intracellular signaling pathway is common in breast cancer (BC) and has been found to be potentially implicated in resistance to endocrine and anti-HER2 therapies. Targeting the PI3K/Akt/mTOR pathwa...
  9. Clinical utility of exemestane in the treatment of breast cancer.

    International Journal of Women s Health 7:551 (2015) PMID 26064072 PMCID PMC4455847

    Breast cancer is the most prevalent cancer in women, causing a significant mortality worldwide. Different endocrine strategies are available for the treatment of hormone-sensitive breast cancer, including antiestrogen tamoxifen and fulvestrant, as well as third-generation aromatase inhibitors (A...
  10. Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions.

    World Journal of Clinical Oncology 5(5):990 (2014) PMID 25493235 PMCID PMC4259959

    About 75% of all breast cancers are estrogen receptor (ER)-positive. They generally have a more favorable clinical behavior, prognosis, and pattern of recurrence, and endocrine therapy forms the backbone of treatment. Anti-estrogens (such as tamoxifen and fulvestrant) and aromatase inhibitors (s...
  11. FDG avidity at PET/CT during adjuvant hormonal therapy in patients with breast cancer.

    Clinical Nuclear Medicine 39(2):e135 (2014) PMID 24398430

    We aim to retrospectively evaluate the impact of hormone therapy (HT) on FDG avidity of metastatic lesions in patients with breast cancer (BC) undergoing PET/CT. Three hundred eight patients with BC were scanned with PET/CT at 2 Italian institutions (mean time from diagnosis 4 yrs, range: 1-24 y...
  12. Current status and future perspectives in the endocrine treatment of postmenopausal, hormone receptor-positive metastatic breast cancer.

    Expert Opinion on Pharmacotherapy 13(15):2143 (2012) PMID 22984936

    Endocrine therapy is a fundamental component of the therapeutic repertoire for treatment of metastatic, hormone receptor-positive breast cancer. Inevitably, however, tumors develop resistance to these compounds, and overcoming this phenomenon is a key motivator of research in this field. This re...
  13. Potential of afatinib in the treatment of patients with HER2-positive breast cancer.

    Breast Cancer Targets and Therapy 4:131 (2012) PMID 24367201 PMCID PMC3846413

    In the absence of treatment, overexpression of the human epidermal growth factor receptor 2 (HER2) predicts a poor prognosis in breast cancer. In the last decade, monoclonal antibodies and small molecule tyrosine kinase inhibitors have significantly improved the outcome of HER2-positive breast c...
  14. Hitting multiple targets in HER2-positive breast cancer: proof of principle or therapeutic opportunity?

    Expert Opinion on Pharmacotherapy 12(4):549 (2011) PMID 21208143

    Pharmacological targeting of the tyrosine kinase receptor HER2 with the monoclonal antibody trastuzumab has dramatically changed the outlook of HER2-positive breast cancer patients. However, HER2 is part of a more complex biological network that, when deregulated, plays a central role in sustain...
  15. Trastuzumab beyond progression in retrospective analyses: an issue of equal opportunities.

    Oncologist 16(4):534 (2011) PMID 21393343 PMCID PMC3228112